SARTORIUS AG UNSP.ADR 1/5 Total Liabilities

Latest as of March 2026: €5.98 Billion EUR ≈ $6.99 Billion USD

SARTORIUS AG UNSP.ADR 1/5 total liabilities. Based on the latest financial reports, SARTORIUS AG UNSP.ADR 1/5 (SRT4) has total liabilities worth €5.98 Billion EUR (≈ $6.99 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See SARTORIUS AG UNSP.ADR 1/5 (SRT4) liquidity interval to measure how many days the company can operate on defensive assets alone.

Total Liabilities of SARTORIUS AG UNSP.ADR 1/5 (2021–2025)

Total liabilities of SARTORIUS AG UNSP.ADR 1/5 from 2021 to 2025. This chart illustrates how SARTORIUS AG UNSP.ADR 1/5's total liabilities have evolved over time, based on quarterly financial data. Check SRT4 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

SARTORIUS AG UNSP.ADR 1/5 Competitors by Total Liabilities

The table below lists competitors of SARTORIUS AG UNSP.ADR 1/5 ranked by their total liabilities.

Company Country Total Liabilities
Ralliant Corporation Common Stock
NYSE:RAL
USA $2.13 Billion
TPG Inc
NASDAQ:TPG
USA $10.29 Billion
Fibra UNO
MX:FUNO11
Mexico MX$165.33 Billion
PSP SWISS ADR 1/5/SF1050
F:P7S0
Germany €4.53 Billion
Venture Global, Inc.
NYSE:VG
USA $43.95 Billion
SPIE SA
PA:SPIE
France €9.11 Billion
Alexandria Real Estate Equities Inc
NYSE:ARE
USA $14.80 Billion
Inventec Corp
TW:2356
Taiwan NT$255.22 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down SARTORIUS AG UNSP.ADR 1/5's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SARTORIUS AG UNSP.ADR 1/5 assets under control.

Liquidity & Leverage Metrics

SARTORIUS AG UNSP.ADR 1/5 Total Liabilities Ratios Explained

SARTORIUS AG UNSP.ADR 1/5 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.91 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.19 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.61 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SARTORIUS AG UNSP.ADR 1/5's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SARTORIUS AG UNSP.ADR 1/5 (2021–2025)

The table below shows the annual total liabilities of SARTORIUS AG UNSP.ADR 1/5 from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €5.85 Billion
≈ $6.84 Billion
-5.73%
2024-12-31 €6.21 Billion
≈ $7.25 Billion
-11.20%
2023-12-31 €6.99 Billion
≈ $8.17 Billion
+61.79%
2022-12-31 €4.32 Billion
≈ $5.05 Billion
+8.58%
2021-12-31 €3.98 Billion
≈ $4.65 Billion
--

About SARTORIUS AG UNSP.ADR 1/5

F:SRT4 Germany Medical Instruments & Supplies
Market Cap
$7.12 Billion
€6.09 Billion EUR
Market Cap Rank
#2757 Global
#558 in Germany
Share Price
€35.60
Change (1 day)
-3.78%
52-Week Range
€29.20 - €40.20
All Time High
€171.85
About

Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors; software apps for bioreactors and cell culture shake flasks; fermenters; cell culture media, biolayer interferometry, microbiological testing, and fluid management pro… Read more